HOMEPRODUCTSCOMPANYCONTACTFAQResearchDictionaryPharmaSign Up FREE or Login

Contraceptive safety among women with cystic fibrosis: a systematic review.

AbstractBACKGROUND:
With dramatic improvements in life expectancy for cystic fibrosis (CF) patients, contraception for women with CF has become an important issue. There are theoretical concerns that hormonal contraceptive use among women with CF may impact disease severity or risk for other adverse health outcomes, including thrombosis and poor bone health, as well as concerns that malabsorption or altered drug metabolism might impact contraceptive effectiveness.
OBJECTIVE:
To evaluate evidence on the safety and effectiveness of contraceptive methods among women with CF.
SEARCH STRATEGY:
We searched the PubMed database for all articles published from database inception through October 2015.
SELECTION CRITERIA:
We included studies that examined measures of disease severity, other health outcomes or indicators of contraceptive effectiveness among women with CF initiating or continuing a contraceptive method.
RESULTS:
Seven studies met our inclusion criteria. Three observational studies of fair to poor quality suggest that use of oral contraceptives (OCs) does not negatively impact CF disease severity, defined as changes in pulmonary function, number of exacerbations or need for intravenous antibiotics. Three small studies of poor quality reported on contraceptive failure among women with CF using combined hormonal contraceptives (combined OCs, patch or ring). One pregnancy was reported in a patch user out of 43 hormonal contraceptive users across all studies. One pharmacokinetic study reported that women with CF achieve steroid hormone plasma concentrations similar to healthy women after ingestion of combined OCs.
CONCLUSIONS:
Limited evidence suggests that hormonal contraceptive use does not negatively impact disease severity among women with CF and that hormonal contraceptive effectiveness is not impaired by CF. Studies were limited by small sample sizes and short duration of follow-up. No studies examined the effect of hormonal contraception on thrombosis or bone health among women with CF.
AuthorsMaura K Whiteman, Titilope Oduyebo, Lauren B Zapata, Seth Walker, Kathryn M Curtis
JournalContraception (Contraception) Vol. 94 Issue 6 Pg. 621-629 (12 2016) ISSN: 1879-0518 [Electronic] United States
PMID27287694 (Publication Type: Journal Article, Review, Systematic Review)
CopyrightPublished by Elsevier Inc.
Chemical References
  • Contraceptives, Oral, Combined
  • Contraceptives, Oral, Hormonal
Topics
  • Contraception (methods)
  • Contraceptive Devices, Female
  • Contraceptives, Oral, Combined (adverse effects)
  • Contraceptives, Oral, Hormonal (adverse effects, pharmacokinetics)
  • Cystic Fibrosis (physiopathology)
  • Equipment Failure
  • Female
  • Humans
  • Observational Studies as Topic
  • Pregnancy
  • Pregnancy, Unplanned
  • Risk Assessment

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research graph!


Choose Username:
Email:
Password:
Verify Password:
Enter Code Shown: